RecruitMe Clinical Trial

Cannabinoid Medication for Adults With OCD
Cannabinoids and OCD
Sponsor:New York State Psychiatric Institute
Enrolling:Male and Female Patients
Age Range:Between 18 and 60 years old
IRB Number:7239
U.S. Government ID:NCT02911324
Contact: Marissa Raskin: 646-774-8062 / Marissa.Raskin@nyspi.columbia.edu
Additional Study Information:

The purpose of this pilot research study is to test the effects of a medication called nabilone (Cesamet) in adults with obsessive-compulsive disorder (OCD). Participants will receive either nabilone on its own, or nabilone in combination with a form of cognitive-behavioral therapy (CBT) called exposure and response prevention (EX/RP). Nabilone is a synthetic cannabinoid and acts on the brain's "endocannabinoid system," which has been hypothesized to play a role in OCD. Nabilone is approved by the FDA for the treatment of chemotherapy-induced nausea and vomiting. It is not FDA-approved for treating OCD.

This study is closed
Investigator
Helen Simpson, MD, PhD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:

Marissa Raskin

Marissa.Raskin@nyspi.columbia.edu

646-774-8062

YesYesNo3